US2011033431A1PendingUtilityA1

Type a2 botulinum toxin preparation

62
Assignee: CHEMO SERO THERAPEUT RES INSTPriority: Mar 31, 2008Filed: Mar 31, 2009Published: Feb 10, 2011
Est. expiryMar 31, 2028(~1.7 yrs left)· nominal 20-yr term from priority
Inventors:Shinji NakahiraYasushi ToriiYoshitaka GotoMiho ShinmuraSatomi MunechikaSachio OkudaShunji Kozaki
A61K 38/4893A61P 21/00A61K 38/164A61P 21/02Y02A50/30
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical preparation for use in a patient who has a neutralizing antibody to a botulinum toxin from type A1 Clostridium botulinum (type A1 botulinum toxin), said preparation comprising as an active ingredient 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX); a medicament for treating a disease with muscle overactivity for use in a patient who has a neutralizing antibody to a type A1 botulinum toxin, said medicament comprising as an active ingredient said A2 NTX; a method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin, said method comprising administering said A2 NTX to the patient; and a method for use of A2 NTX in a patient who has said neutralizing antibody. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation comprising a type A1 botulinum toxin.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical preparation for use in a patient who has a neutralizing antibody to a  botulinum  toxin from type A1  Clostridium botulinum  (type A1  botulinum  toxin), said preparation comprising as an active ingredient 150 kDa type A neurotoxin from type A2  Clostridium botulinum  (A2 NTX). 
     
     
         2 . A medicament for treating a disease with muscle overactivity for use in a patient who has a neutralizing antibody to a type A1  botulinum  toxin, said medicament comprising as an active ingredient A2 NTX. 
     
     
         3 . A method for treating a patient who has a neutralizing antibody to a type A1  botulinum  toxin, said method comprising administering A2 NTX to the patient. 
     
     
         4 . A method for treating a patient suffering from a disease with muscle overactivity who has a neutralizing antibody to a type A1  botulinum  toxin, said method comprising administering A2 NTX to the patient. 
     
     
         5 . Use of A2 NTX in a patient who has a neutralizing antibody to a type A1  botulinum  toxin. 
     
     
         6 . Use of A2 NTX in a patient suffering from a disease with muscle overactivity who has a neutralizing antibody to a type A1  botulinum  toxin.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.